Source link : https://newshealth.biz/health-news/dreamm-20-hints-at-a-more-tolerable-path-for-bcma-targeted-therapy-in-myeloma/
(MedPage Today) — At the recent American Society of Clinical Oncology (ASCO) meeting, early data from the DREAMM-20 trial showed that the naked B-cell maturation antigen (BCMA)-targeted monoclonal antibody belantamab — without the cytotoxic… Source link : https://www.medpagetoday.com/meetingcoverage/ascofuturefocusmm/116340 Author : Publish date : 2025-07-01 19:15:00 Copyright for syndicated content belongs to the linked Source.
The post DREAMM-20 Hints at a More Tolerable Path for BCMA-Targeted Therapy in Myeloma first appeared on News Health.
—-
Author : News Health
Publish date : 2025-07-01 19:15:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8